RT Journal Article
SR Electronic
T1 G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 354
OP 374
DO 10.20892/j.issn.2095-3941.2018.0030
VO 15
IS 4
A1 Angel Mauricio Castro-Gamero
A1 Julia Alejandra Pezuk
A1 María Sol Brassesco
A1 Luiz Gonzaga Tone
YR 2018
UL http://www.cancerbiomed.org/content/15/4/354.abstract
AB Glioblastoma (GBM) is one of the deadliest tumors and has a median survival of 3 months if left untreated. Despite advances in rationally targeted pharmacological approaches, the clinical care of GBM remains palliative in intent. Since the majority of altered signaling cascades involved in cancer establishment and progression eventually affect cell cycle progression, an alternative approach for cancer therapy is to develop innovative compounds that block the activity of crucial molecules needed by tumor cells to complete cell division. In this context, we review promising ongoing and future strategies for GBM therapeutics aimed towards G2/M inhibition such as anti-microtubule agents and targeted therapy against G2/M regulators like cyclin-dependent kinases, Aurora inhibitors, PLK1, BUB, 1, and BUBR1, and survivin. Moreover, we also include investigational agents in the preclinical and early clinical settings. Although several drugs were shown to be gliotoxic, most of them have not yet entered therapeutic trials. The use of either single exposure or a combination with novel compounds may lead to treatment alternatives for GBM patients in the near future.